Gene therapy for colorectal cancer

被引:4
作者
Kerr, DJ [1 ]
Seymour, LW [1 ]
Maruta, F [1 ]
机构
[1] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
关键词
cancer treatment; colorectal cancer; gene therapy; immunotherapy; prodrug therapy; tumour targeting; vector;
D O I
10.1517/14712598.3.5.779
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Colorectal cancer is an important public health problem worldwide. Gene therapy has therapeutic potential for patients with advanced or recurrent colorectal cancer, incurable by conventional treatments. To date, many strategies of gene therapy have been explored, including mutant gene correction, prodrug activation, immune stimulation and genetically-modified oncolytic viruses. Although the preclinical results, of gene therapy for colorectal cancer have shown promise, gene therapy is still at an early stage of clinical development and has not yet shown a significant therapeutic benefit for patients. The main obstacles for introduction of gene therapy to patients are poor targeting selectivity of the vectors and inefficient gene transfer. As the science supporting tumour-selective vectors evolves, gene therapy may expand rapidly in the clinical practice of colorectal cancer treatment.
引用
收藏
页码:779 / 788
页数:10
相关论文
共 56 条
  • [1] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
    Arap, W
    Pasqualini, R
    Ruoslahti, E
    [J]. SCIENCE, 1998, 279 (5349) : 377 - 380
  • [2] Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer
    Bennett, JJ
    Delman, KA
    Burt, BM
    Mariotti, A
    Malhotra, S
    Zager, J
    Petrowsky, H
    Mastorides, S
    Federoff, H
    Fong, YM
    [J]. CANCER GENE THERAPY, 2002, 9 (11) : 935 - 945
  • [3] BOYEL P, 2002, BR MED B, V64, P1
  • [4] The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen
    Bramson, JL
    Wan, YH
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (01) : 75 - 85
  • [5] Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells
    Burrows, FJ
    Gore, M
    Smiley, WR
    Kanemitsu, MY
    Jolly, DJ
    Read, SB
    Nicholas, T
    Kruse, CA
    [J]. CANCER GENE THERAPY, 2002, 9 (01) : 87 - 95
  • [6] Chen SH, 1996, CANCER RES, V56, P3758
  • [7] CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO
  • [8] 2-P
  • [9] Chung-Faye G, 2001, CLIN CANCER RES, V7, P2662
  • [10] Gene therapy strategies for colon cancer
    Chung-Faye, GA
    Kerr, DJ
    Young, LS
    Searle, PF
    [J]. MOLECULAR MEDICINE TODAY, 2000, 6 (02): : 82 - 87